711 related articles for article (PubMed ID: 19148488)
21. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
22. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.
Rowse GJ; Ritland SR; Gendler SJ
Cancer Res; 1998 Jun; 58(12):2675-9. PubMed ID: 9635596
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of Muc1 in MMTV-c-Neu tumors.
Adriance MC; Gendler SJ
Oncogene; 2004 Jan; 23(3):697-705. PubMed ID: 14737104
[TBL] [Abstract][Full Text] [Related]
24. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
Daphna-Iken D; Shankar DB; Lawshé A; Ornitz DM; Shackleford GM; MacArthur CA
Oncogene; 1998 Nov; 17(21):2711-7. PubMed ID: 9840935
[TBL] [Abstract][Full Text] [Related]
25. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Bentires-Alj M; Neel BG
Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
[TBL] [Abstract][Full Text] [Related]
26. The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer.
Gardner HP; Ha SI; Reynolds C; Chodosh LA
Cancer Res; 2000 Oct; 60(19):5571-7. PubMed ID: 11034105
[TBL] [Abstract][Full Text] [Related]
27. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX
Oncogene; 2001 Mar; 20(12):1445-54. PubMed ID: 11313888
[TBL] [Abstract][Full Text] [Related]
29. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
[TBL] [Abstract][Full Text] [Related]
30. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.
Trimble MS; Xin JH; Guy CT; Muller WJ; Hassell JA
Oncogene; 1993 Nov; 8(11):3037-42. PubMed ID: 7692372
[TBL] [Abstract][Full Text] [Related]
31. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene.
Barbieri I; Quaglino E; Maritano D; Pannellini T; Riera L; Cavallo F; Forni G; Musiani P; Chiarle R; Poli V
Mol Carcinog; 2010 Feb; 49(2):114-20. PubMed ID: 20027636
[TBL] [Abstract][Full Text] [Related]
32. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4.
Jackson-Fisher AJ; Bellinger G; Shum E; Duong JK; Perkins AS; Gassmann M; Muller W; Kent Lloyd KC; Stern DF
Oncogene; 2006 Sep; 25(41):5664-72. PubMed ID: 16652155
[TBL] [Abstract][Full Text] [Related]
33. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
34. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.
Reddy KB; McGowen R; Schuger L; Visscher D; Sheng S
Oncogene; 2001 Oct; 20(45):6538-43. PubMed ID: 11641778
[TBL] [Abstract][Full Text] [Related]
35. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
[TBL] [Abstract][Full Text] [Related]
36. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice.
Henry MD; Triplett AA; Oh KB; Smith GH; Wagner KU
Oncogene; 2004 Sep; 23(41):6980-5. PubMed ID: 15286714
[TBL] [Abstract][Full Text] [Related]
37. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
[TBL] [Abstract][Full Text] [Related]
38. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu.
Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS
Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156
[TBL] [Abstract][Full Text] [Related]
39. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
40. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.
Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE
Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
